Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database

作者：Chiara Gastaldon, Georgios Schoretsanitis, Elena Arzenton, Emanuel Raschi, Davide Papola, Giovanni Ostuzzi, Ugo Moretti, Erich Seifritz, John M. Kane, Gianluca Trifirò, Corrado Barbui · 发表于：Drug Safety · 年份：2022 · DOI：10.1007/s40264-022-01246-4 · 被引用次数：63 · 研究领域：Pharmacovigilance and Adverse Drug Reactions、Treatment of Major Depression、Alcoholism and Thiamine Deficiency

INTRODUCTION: Evidence is lacking on withdrawal syndrome related to individual antidepressants and relevant risk factors for severe reactions. OBJECTIVE: To ascertain whether antidepressants are associated with an increased reporting of withdrawal syndrome as compared with other medications, and to investigate risk factors for severe reactions. METHODS: , the WHO global database of individual case safety reports of suspected adverse drug reactions. We performed a disproportionality analysis of reports of antidepressant-related withdrawal syndrome (calculating reporting odds ratio [ROR] and Bayesian information component [IC]). We compared antidepressants to all other drugs, to buprenorphine (positive control), and to each other within each class of antidepressants (selective serotonin reuptake inhibitors [SSRIs], tricyclics and other antidepressants). Antidepressants with significant disproportionate reporting were ranked in terms of clinical priority. Serious versus non-serious reactions were compared. RESULTS: There were 31,688 reports of antidepressant-related withdrawal syndrome were found. A disproportionate reporting was detected for 23 antidepressants. The estimated ROR for antidepressants altogether, compared to all other drugs, was 14.26 (95% CI 14.08-14.45), 17.01 for other antidepressants (95% CI 16.73-17.29), 13.65 for SSRIs (95% CI 13.41-13.90) and 2.8 for tricyclics (95% CI 2.59-3.02). Based on clinical priority ranking, the strongest disproportionate reporting ...